Abstract
Ascites becomes refractory to medical treatmentin nearly 10% of cirrhotic patients, who then requirerepeated large-volume paracentesis. In this prospectivestudy we evaluated the use of transjugular intrahepatic portosystemic shunt (TIPS) in 30 patients withrefractory ascites. TIPS was successful in all andresulted in a 54% reduction in portacaval gradient (from22.8 ± 0.8 to 10.4 ± 0.6 mm Hg). Ascitesbecame easily controlled with diuretics in 26 patientsfollowing TIPS. Ascites recurrence associated with shuntstenosis was observed during follow-up in eightpatients; revision could be undertaken in five of themand resulted in good control of ascites. Inresponders, a marked decrease in plasma aldosterone andrenin activity, a reduction in serum creatinine, and arise in urinary sodium excretion were observed.Creatinine and inulin clearances improved significantly;PAH clearance remained unchanged. However, new-onset orworsening hepatic encephalopathy was seen in 14patients. Severe disabling chronic encephalopathyoccurred in five patients; it could be reversedsuccessfully by balloon occlusion of the shunt in three.The cumulative survival rate was 41 and 34% at 1 and 2years, respectively. In summary, TIPS can controlrefractory ascites in a majority of patients but isassociated with a high rate of chronic disabling HE. Inaddition, the survival rate is poor. Randomized trialsare needed to evaluate the exact role of TIPS in the management of refractory ascites. It isunlikely to improve survival but can ameliorate qualityof life in nontransplant candidates and be useful as abridge to transplantation, in particular, to improve denutrition associated with longstanding tenseascites.
Article PDF
Similar content being viewed by others
REFERENCES
Olafson S, Blei AT: Diagnosis and management of ascites in the age of TIPS. Am J Roentgenol 165:9–15, 1995
Gines P, Arroyo V, Vargas V, Planas R, Casafont F, Panes J, Hoyos M, Viladomiu L, Rimola A, Morillas R, Salmeron JM, Gines A, Esteban R, Rodes J: Paracentesis with intravenous infusion of albumin as compared with peritoneous shunting in cirrhosis with refractory ascites. N Engl J Med 325:829–835, 1991
Stanley MM, Ochi S, Lee KL, Veterans Administration Cooperative Study on Treatment of Alcoholic Cirrhosis with Ascites: Peritoneous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. N Engl J Med 321:1632–1638, 1989
Welch HF, Welch CS, Carter JH: Prognosis after surgical treatment of ascites. Results of side-to-side shunt in 40 patients. Surgery 56:75–82, 1964
Franco D, Vons C, Traynor O, Smajda C: Should portosystemic shunt be reconsidered in the treatment of untractable ascites in cirrhosis. Arch Surg 123:987–991, 1988
Lafortune M, Martinet JP, Denys A, Dufresne MP, Colombato L, Pomier-Layrargues G: Short and long term hemodynamic effects of TIPS: A Doppler/manometric study. Am J Roentgenol 164:970–1002, 1995
De Langhe J, Bellon J, De Buyzere M, Van Daele G, Leroux-Roels G: Elimination of glucose interference in enzymatic determination of inulin. Clin Chem 37:2017–18, 1991
Brun C: A rapid method for the determination of para-aminohippuric acid in kidney function tests. J Lab Clin Med 37:955–958, 1951
Desmassieux S, Corneille L, Lachance S, Carriere S: Determination of free and conjugated catecholamines and L-3,4-dehydroxyphenylalanin in plasma and urine; evidence of a catechol-a-methyl transferase inhibitor in uraemia. Clin Chim Acta 115:377–391, 1981
Runyon BA: Care of patients with ascites. N Engl J Med 330:337–342, 1994
Ferral HJ, Bjarnason H, Wegryn SA, Rengel GJ, Mazarian GK, Rank JM, Tadavarthy SM, Hunter DW, Castaneda-Zuniga WR: Refractory ascites: Early experience in treatment with transjugular intrahepatic portosystemic shunt. Radiology 189:795–801, 1993
Quiroga J, Sangro B, Nunez M, Bilbao I, Longo J, Garcia-Villareal L, Zozanya JM, Betes M, Herrero JL, Prieto J: Transjugular intra-hepatic portal-systemic shunt in the treatment of refractory ascites: Effect on clinical, renal, humoral and hemodynamic parametes. Hepatology 21:986–994, 1995
Somberg KA, Lake JR, Tomlanouich J, Laberge JM, Feldstein V, Bass NM: Transjugular intrahepatic porto-systemic shunts for refractory ascites: Assessment of clinical and hormonal response and renal function. Hepatology 21:709–716, 1995
Ochs A, Rossle M, Haag K, Havenstein KH, Deibert P, Siegerstetter V, Huonker M, Langer M, Blum HE: The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med 332:1193–1197, 1995
Wong F, Sniderman K, Liu P, Allidina Y, Sherman M, Blendis L: Transjugular intrahepatic portosystemic stent shunt: Effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern Med 122:816–822, 1995
Fenyves D, Dufresne MP, Raymond J, Lafortune M, Willems B, Pomier-Layrargues G: Successful reversal of chronic incapacitating post-TIPS encephalopathy by balloon occlusion of the stent. Can J Gastroenterol 8:75–80, 1994
Sanyal AJ, Freedman AM, Schiffman ML, Purdum PP, Luketic VA, Cheatham AK: Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. Hepatology 20:46–55, 1994
Somberg KA, Riegler JL, Laberge JM, Doherty-Simor MM, Bachetti P, Roberts JP, Lake JR: Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: Incidence and risk factors. Am J Gastroenterol 90:549–55, 1995
Rights and permissions
About this article
Cite this article
Dufresne, M.P., Spahr, L., Lafortune, M. et al. Treatment of Refractory Ascites Using Transjugular Intrahepatic Portosystemic Shunt (TIPS) (A Caution). Dig Dis Sci 42, 161–166 (1997). https://doi.org/10.1023/A:1018861827399
Issue Date:
DOI: https://doi.org/10.1023/A:1018861827399